ArticleAdvanced biology2026
A Novel Platform for Fast and Cost-Effective Screening of Immunomodulatory Compounds.
Article in Advanced biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Compounds with immunomodulatory properties are increasingly recognized as valuable adjunctive therapies in pathological conditions associated with immune dysregulation. However, their discovery process is often costly and time-consuming. The aim of this study is to develop a low-cost, simple-to-perform, and reliable method for screening immunomodulatory agents. Human peripheral blood mononuclear cells (PBMNCs) are used as a model system. PBMNCs are isolated by density gradient centrifugation and treated with different immunostimulators and immunosuppressors. By measuring several analytes with a gas analyzer, it is revealed that changes in lactate levels alone can be used as an indicator of immune cell activation/suppression. This finding is further confirmed by measuring the expression of cell surface activation markers and HIF1α using flow cytometry, glucose concentration in PBMNC cultures using a gas analyzer, and levels of TNF-ά and IL-10 by ELISA. The results presented here reveal the simplicity and reliability of this innovative platform for screening immunomodulatory compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.